Lilly Provides Additional Funding to IDRI

The funding will allow IDRI to continue its early phase drug discovery efforts focused on identifying new and better therapies against tuberculosis.

US-based pharmaceutical company Eli Lilly is providing more than $4 million in additional funding to the Infectious Disease Research Institute. The funding will allow IDRI to continue its early phase drug discovery efforts focused on identifying new and better therapies in the fight against tuberculosis, including multidrug-resistant strains known as MDR-TB.

In addition, Lilly will provide more than $1 million in-kind for volunteer time from Lilly scientists and access to the company's drug discovery expertise, chemical libraries, and research tools.

These additional commitments bring Lilly's total support of early stage TB drug discovery efforts through IDRI to more than $20 million - and Lilly's total funding of TB and MDR-TB efforts to more th